Search

Your search keyword '"Goergen, Helen"' showing total 27 results
Start Over Author "Goergen, Helen" Search Limiters Full Text
27 results on '"Goergen, Helen"'

2. Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial

Author

Voltin, Conrad-Amadeus, primary, Mettler, Jasmin, additional, van Heek, Lutz, additional, Goergen, Helen, additional, Müller, Horst, additional, Baues, Christian, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann-Grill, Karolin, additional, Kerkhoff, Andrea, additional, Fuchs, Michael, additional, Sasse, Stephanie, additional, von Tresckow, Bastian, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Kobe, Carsten, additional, and Bröckelmann, Paul J., additional

Published
2021
Full Text
View/download PDF

3. Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Author

Bröckelmann, Paul J, primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann, Karolin, additional, Halbsguth, Teresa V, additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

4. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Author

Bröckelmann, Paul J, primary, Goergen, Helen, primary, Keller, Ulrich, primary, Meissner, Julia, primary, Ordemann, Rainer, primary, Halbsguth, Teresa V, primary, Sasse, Stephanie, primary, Sökler, Martin, primary, Kerkhoff, Andrea, primary, Mathas, Stephan, primary, Hüttmann, Andreas, primary, Bormann, Matthias, primary, Zimmermann, Andreas, primary, Fuchs, Michael, primary, von Tresckow, Bastian, primary, Baues, Christian, primary, Rosenwald, Andreas, primary, Klapper, Wolfram, primary, Kobe, Carsten, primary, Borchmann, Peter, primary, and Engert, Andreas, primary

Published
2019
Full Text
View/download PDF

7. Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma

Author

Engert, Andreas, Goergen, Helen, Markova, Jana, Pabst, Thomas, Meissner, Julia, Zijlstra, Josée M., Král, Zdenek, Eichenauer, Dennis A., Soekler, Martin, Greil, Richard, Kreissl, Stefanie, Scheuvens, Ruth, Eich, Hans, Kobe, Carsten, Dietlein, Markus, Stein, Harald, Fuchs, Michael, Diehl, Volker, and Borchmann, Peter

Subjects
long-term outcome, lcsh:RC633-647.5, Original Article, Advanced stages, lcsh:Diseases of the blood and blood-forming organs, Hodgkin lymphoma
Abstract

The international, randomized phase 3 HD15 trial established 6xeBEACOPP as standard therapy for patients with newly diagnosed advanced-stage Hodgkin lymphoma (HL) within the German Hodgkin Study Group (GHSG). We performed a follow-up analysis to assess long-term efficacy and safety of this approach. Between 2003 and 2008, 2182 patients aged 18 to 60 years were recruited and randomized in a 1:1:1 ratio between 8 or 6 cycles of eBEACOPP or 8 cycles of the dose-dense BEACOPP-14 regimen, each followed by 30 Gy radiotherapy in case of positron emission tomography (PET)-positive residual lesions ≥2.5 cm. The study aimed at demonstrating non-inferiority regarding efficacy of the 2 experimental arms on a significance level of 2.5% each. The intention-to-treat analysis comprised 2126 patients with a median follow-up of 102 months. Ten-year progression-free survival was 81% (97.5% CI 77–85) with 8xeBEACOPP, 84% (80–87) with 6xeBEACOPP, and 84% (80–87) with 8xBEACOPP-14; the non-inferiority margin of 1.51 for the hazard ratio (HR) could be excluded for both comparisons (6xeBEACOPP, HR = 0.7, 97.5% CI 0.5–1.0; 8xBEACOPP-14, HR = 0.9, 97.5% CI 0.7–1.2). Overall survival at 10 years was 88% (85–91), 90% (88–93), and 92% (89–94), respectively. A total of 142 second malignancies corresponding to 10-year cumulative incidences of 10%, 7%, and 7% and standardized incidence ratios of 4.3, 2.5, and 2.8 were reported for 8xeBEACOPP, 6xeBEACOPP, and 8xBEACOPP-14, respectively. This updated analysis of the HD15 trial thus confirms the efficacy and reports on the long-term safety of a shortened first-line chemotherapy consisting of 6xeBEACOPP followed by PET-guided radiotherapy in advanced-stage HL.

Published
2017

8. PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Author

Fuchs, Michael, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Eich, Hans, additional, Baues, Christian, additional, Greil, Richard, additional, Sasse, Stephanie, additional, Zijlstra, Josée M, additional, Lohri, Andreas, additional, Rosenwald, Andreas, additional, von Tresckow, Bastian, additional, Diehl, Volker, additional, Kuhnert, Georg, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2018
Full Text
View/download PDF

9. B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Author

Boell, Boris, primary, Fosså, Alexander, additional, Goergen, Helen, additional, Kamper, Peter, additional, Leppa, Sirpa, additional, Molin, Daniel, additional, Meissner, Julia, additional, Ritter, Ellen, additional, Christensen, Jacob H., additional, Hutchings, Martin, additional, Fuchs, Michael, additional, Engert, Andreas, additional, Kobe, Carsten, additional, and Borchmann, Peter, additional

Published
2018
Full Text
View/download PDF

12. Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Author

Borchmann, Peter, primary, Goergen, Helen, additional, Kobe, Carsten, additional, Lohri, Andreas, additional, Greil, Richard, additional, Eichenauer, Dennis A., additional, Zijlstra, Josée M, additional, Markova, Jana, additional, Meissner, Julia, additional, Feuring-Buske, Michaela, additional, Hüttmann, Andreas, additional, Dierlamm, Judith, additional, Sökler, Martin, additional, Krause, Stefan W., additional, Eich, Hans, additional, Baues, Christian, additional, Kreissl, Stefanie, additional, Fuchs, Michael, additional, Dietlein, Markus, additional, and Engert, Andreas, additional

Published
2017
Full Text
View/download PDF

14. Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Author

Kreissl, Stefanie, primary, Goergen, Helen, additional, von Tresckow, Bastian, additional, Behringer, Karolin, additional, Markova, Jana, additional, Lohri, Andreas, additional, Meissner, Julia, additional, Zijlstra, Josée M, additional, Greil, Richard, additional, Topp, Max S., additional, Sökler, Martin, additional, Döhner, Hartmut, additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2015
Full Text
View/download PDF

15. Phase II Study of Ofatumumab in Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report from the German Hodgkin Study Group

Author

Eichenauer, Dennis A., primary, Goergen, Helen, additional, Pluetschow, Annette, additional, Behringer, Karolin, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul, additional, Fuchs, Michael, additional, Böll, Boris, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2015
Full Text
View/download PDF

18. Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Author

Hay, Annette E., primary, Klimm, Beate, additional, Chen, Bingshu E., additional, Goergen, Helen, additional, Shepherd, Lois E., additional, Fuchs, Michael, additional, Gospodarowicz, Mary, additional, Borchmann, Peter, additional, Connors, Joseph M., additional, Markova, Jana, additional, Crump, Michael, additional, Lohri, Andreas, additional, Winter, Jane N., additional, Dörken, Bernd, additional, Pearcey, Robert G., additional, Diehl, Volker, additional, Horning, Sandra J., additional, Eich, Hans Theodor, additional, Engert, Andreas, additional, and Meyer, Ralph M., additional

Published
2012
Full Text
View/download PDF

19. Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Author

Behringer, Karolin, primary, Mueller, Horst, additional, Goergen, Helen, additional, Thielen, Indra, additional, Eibl, Angelika, additional, Stumpf, Volker, additional, Wessels, Carsten, additional, Wiehlpuetz, Martin, additional, Rosenbrock, Johannes, additional, Halbsguth, Teresa, additional, Reiners, Katrin S., additional, Schober, Thomas, additional, Renno, Joerg H, additional, von Wolff, Michael, additional, van der Ven, Katrin, additional, Kuehr, Marietta, additional, Fuchs, Michael, additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2012
Full Text
View/download PDF

21. Fertility and Gonadal Function After Treatment of Early Unfavorable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG)

Author

Behringer, Karolin, primary, Thielen, Indra, additional, Mueller, Horst, additional, Goergen, Helen, additional, Eibl, Angelika, additional, Rosenbrock, Johannes, additional, Halbsguth, Teresa, additional, Reiners, Katrin S., additional, Diehl, Volker, additional, Engert, Andreas, additional, and Borchmann, Peter, additional

Published
2011
Full Text
View/download PDF

22. Combined Modality Treatment with Intensified Chemotherapy and Dose-Reduced Involved Field Radiotherapy in Patients with Early Unfavourable Hodgkin Lymphoma (HL): Final Analysis of the German Hodgkin Study Group (GHSG) HD11 Trial.

Author

Borchmann, Peter, primary, Diehl, Volker, additional, Goergen, Helen, additional, Mueller, Horst, additional, Mueller, Rolf Peter, additional, Eich, Hans T., additional, Mueller-Hermelink, Hans Konrad, additional, Herrmann, Richard, additional, Markova, Jana, additional, Ho, Anthony D., additional, Hiddemann, Wolfgang, additional, Doerken, Bernd, additional, Greil, Richard, additional, and Engert, Andreas, additional

Published
2009
Full Text
View/download PDF

26. PET-guided Treatment in Patients with Advanced-stage Hodgkin's Lymphoma (HD18): Final Results of An Open-label, International, Randomised Phase 3 Trial by the German Hodgkin Study Group.

Author

Borchmann, Peter, Goergen, Helen, Kobe, Carsten, Lohri, Andreas, Greil, Richard, Eichenauer, Dennis A., Zijlstra, Josée M., Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Hüttmann, Andreas, Dierlamm, Judith, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S., Hitz, Felicitas, and Bentz, Martin

Published
2018

27. Brentuximab vedotin for relapsed or refractory CD30+hematologic malignancies: the German Hodgkin Study Group experience

Author

Rothe, Achim, Sasse, Stephanie, Goergen, Helen, Eichenauer, Dennis A., Lohri, Andreas, Jäger, Ulrich, Bangard, Christopher, Böll, Boris, von Bergwelt Baildon, Michael, Theurich, Sebastian, Borchmann, Peter, and Engert, Andreas

Abstract

The CD30-targeting Ab-drug conjugate brentuximab vedotin (SGN-35) was recently approved for the treatment of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Administration. In the present study, we report the experience of the German Hodgkin Study Group with brentuximab vedotin as single agent in 45 patients with refractory or relapsed CD30+Hodgkin lymphoma who were treated either in a named patient program (n = 34) or in the context of a safety study associated with the registration program of this drug. In these very heavily pretreated patients, an objective response rate of 60%, including 22% complete remissions, could be documented. The median duration of response was 8 months. This retrospective analysis supports the previously reported excellent therapeutic efficacy of brentuximab vedotin in heavily pretreated CD30+malignancies. This trial was registered at www.clinicaltrials.govwith identifier NCT01026233.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results